MedTrace Logo

To Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects

NCT03291418 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 258

Last updated 2018-06-06

No results posted yet for this study

Summary

A Double-Blind, Controlled Study to Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects

Conditions

  • Gastric Ulcer

Interventions

DRUG

ATB-346 OR Placebo

Comparison of gastrointestinal effects

DRUG

Naproxen sodium

Comparison of gastrointestinal effects

Sponsors & Collaborators

  • Antibe Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Deepen Patel, MD · Topstone Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-08
Primary Completion
2018-03-31
Completion
2018-04-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03291418 on ClinicalTrials.gov